Use of Partially HLA-Matched Multivirus-Specific T Cells to Treat EBV, CMV, Adenovirus, BK, and JC Virus Infections After Allogeneic Stem Cell or CAR-T Cell Transplant

What this Trial Is About

Researchers are evaluating the use of virus-specific T cells VSTs from donors partially matched by human leukocyte antigen HLA to treat viral infections that occur after an allogeneic hematopoietic stem cell transplant HSCT or CAR-T cell therapy. These infections, caused by viruses like Epstein Barr virus, cytomegalovirus, adenovirus, and BK virus, can persist or recur despite standard treatments and pose serious risks to patients with weakened immune systems post-transplant. The study aims to further develop and assess banked multivirus-specific T cells as an off the shelf treatment option with reduced side effects. Participants will receive a thawed infusion of partially HLA-matched multivirus-specific T cells through an intravenous line. Patients may receive one or more doses depending on their response and tolerance, with doses spaced at least 14 days apart. Prior to infusion, medications like diphenhydramine and acetaminophen may be given to prevent allergic reactions. The treatment dose depends on body surface area, and if the initial donors cells are insufficient or less optimal, cells from a different donor may be used for subsequent infusions. Throughout the study, participants will be monitored by their transplant doctors, including weekly clinic visits for six weeks after infusion. Blood samples may be collected at various points to evaluate the treatments effect on virus levels and immune response. Study participation lasts approximately one year after the last T cell infusion, during which safety, antiviral response, and potential side effects such as graft versus host disease will be assessed. Blood specimens may also be stored for future research with confidentiality maintained.

TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.